BAY 987519

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hepatocellular CarcinomaToxicityESSDrugTIAAlport SyndromeMTAP-Deleted Solid Tumors

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

1

BAY 987519

Bayer

Phase 2

12

Ibrance

Pfizer

Preclinical

13

Viread

Gilead

Preclinical

14

Sovaldi

Gilead

Preclinical

15

Hepsera

Gilead

Preclinical

—6

Coreg

Akero Therapeutics

Preclinical

27

Doptelet

AAkarx

Preclinical

18

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

19

Vermox

WWim Janssens

Preclinical

110

Statin

Bristol-Myers Squibb

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

TIA2 trials

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

Completed·Bayer·N/A·NCT02869113·65 enrolled

Evaluation of the Stinging Potential in Human Eyes

Completed·Bayer·N/A·NCT02872207·40 enrolled

Absorption1 trial

A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants

Completed·Bayer·Phase 1·NCT06412926·14 enrolled

Type 2 Diabetes Mellitus1 trial

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Completed·Bayer·Phase 2·NCT01968668·96 enrolled

ESS1 trial

Supervised Outdoor-Use Test to Assess the Safety of a Sunscreen C-Spray on Sport Users

Completed·Bayer·N/A·NCT02857478·98 enrolled

Renal Cell Carcinoma1 trial

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Completed·Bayer·Phase 2·NCT00044564·54 enrolled

14 more indications

Venous Thromboembolism1 trial

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Completed·Bayer·Phase 3·NCT02064439·3,365 enrolled

Effectiveness1 trial

Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy

Withdrawn·Bayer··NCT01961388

Drug1 trial

A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.

Recruiting·Bayer·Phase 1·NCT07176728·16 enrolled

Congestive Heart Failure1 trial

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Completed·Bayer·Phase 2·NCT03901729·482 enrolled

Phase II1 trial

BAY 77-1931 Long-term Extension From Phase II Study

Completed·Bayer·Phase 2·NCT00769496·145 enrolled

Prostate Cancer1 trial

Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects

Completed·Bayer·Phase 1·NCT02363855·9 enrolled

Hemophilia1 trial

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors

Completed·Bayer·Phase 1·NCT01921855·16 enrolled

Solid Tumors1 trial

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Completed·Bayer·Phase 1·NCT02639091·36 enrolled

Toxicity1 trial

18794 - Human Photo Toxicity Test

Completed·Bayer·N/A·NCT02751372·35 enrolled

Vasomotor Symptoms1 trial

ZK283197 for Treatment of Vasomotor Symptoms

Completed·Bayer·Phase 2·NCT00537836·116 enrolled

Alport syndrome1 trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome

Active, not recruiting·Bayer·Phase 2·NCT07211685·60 enrolled

MTAP-deleted Solid Tumors1 trial

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.

Recruiting·Bayer·Preclinical·NCT06914128·450 enrolled

Hepatocellular Carcinoma1 trial

A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)

Recruiting·Bayer·Phase 1·NCT06764316·148 enrolled

Unspecified9 trials

Sun Protection Factor (SPF) - Static and Water Resistant Assay

Completed·Bayer·N/A·NCT02857738·12 enrolled

Sun Protection Factor Assay (316/2016)

Completed·Bayer·N/A·NCT02994992·12 enrolled

Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay

Completed·Bayer·N/A·NCT02872233·6 enrolled

Show 6 more trials

Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium

Completed·Bayer·Phase 1·NCT00941057·43 enrolled

Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) - Assay

Completed·Bayer·N/A·NCT02872246·11 enrolled

18612 - Sun Protection Factor Assay

Completed·Bayer·N/A·NCT02760576·10 enrolled

18611 - Sun Protection Factor Assay

Completed·Bayer·N/A·NCT02760563·10 enrolled

Sun Protection Factor (SPF) Assay

Completed·Bayer·N/A·NCT02857725·12 enrolled

BAY1238097, First in Man

Terminated·Bayer·Phase 1·NCT02369029·8 enrolled

Details

Drug Info

Related News